Generic Name and Formulations:
Acetaminophen 500mg, pamabrom 25mg; caplets.
Bayer Corp, Consumer Care Div.
Indications for MIDOL:
2 caplets every 6hrs; max 6/day.
<12yrs: consult physician.
Concomitant other acetaminophen-containing products.
Acetaminophen: hepatic disease. Pyrilamine: asthma, emphysema, other lower respiratory disorders. Glaucoma. GI or urinary obstruction. Discontinue if skin or allergic reactions occur. Reevaluate if pain worsens or lasts >10 days or fever persists or worsens >3 days. Pregnancy. Nursing mothers.
Analgesic + diuretic.
Acetaminophen: increased risk of hepatotoxicity if overdosage or ≥3 alcoholic drinks/day. Pyrilamine: potentiates CNS depression with alcohol, other CNS depressants. Caution with warfarin, sedatives, or tranquilizers.
Acetaminophen: hepatotoxicity (overdosage). Pyrilamine: drowsiness, dizziness, paradoxical excitation (esp. in children). Caffeine: nervousness, irritability, sleeplessness, occasional palpitations.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified